Rituximab vs mycophenolate and vs cyclophosphamide pulses for induction therapy of active lupus nephritis: A clinical observational study

Rheumatology (United Kingdom)

Volumn 53, Issue 9, 2014, Pages 1570-1577

  Moroni, Gabriella ^a   Raffiotta, Francesca ^a   Trezzi, Barbara ^b   Giglio, Elisa ^a   Mezzina, Nicoletta ^b   Del Papa, Nicoletta ^c   Meroni, Pierluigi ^d   Messa, Piergiorgio ^a   Sinico, Alberto Renato ^b  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b SAN CARLO BORROMEO HOSPITAL   (Italy)

^c ISTITUTO ORTOPEDICO GAETANO PINI   (Italy)

^d ISTITUTO AUXOLOGICO ITALIANO   (Italy)

Author keywords

Cyclophosphamide pulse therapy; Lupus nephritis; Mycophenolate therapy; Rituximab therapy; Systemic lupus erythematosus

Indexed keywords

CREATININE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; HEMOGLOBIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; PARACETAMOL; PREDNISONE; RITUXIMAB; SERUM ALBUMIN;

ABSCESS; ACUTE GASTROENTERITIS; ADULT; AMENORRHEA; ANEMIA; ARTICLE; BLOOD TRANSFUSION; CHRONIC KIDNEY FAILURE; CHRONICITY; CORTICOSTEROID THERAPY; CREATININE BLOOD LEVEL; DIARRHEA; DISEASE DURATION; DRUG DOSE REDUCTION; DRUG HYPERSENSITIVITY; EVENING DOSAGE; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; GASTROENTERITIS; HERPES ZOSTER; HUMAN; HUMAN TISSUE; KIDNEY BIOPSY; LEUKOPENIA; LUPUS ERYTHEMATOSUS NEPHRITIS; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; NEPHROTIC SYNDROME; OBSERVATIONAL STUDY; OTITIS; OUTCOME ASSESSMENT; PNEUMONIA; PRIORITY JOURNAL; PROTEINURIA; PRURITUS; REMISSION; RHINITIS; SEPSIS;

EID: 84906839444     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ket462     Document Type: Article

References (37)

1. Bertsias GK, Tektonidou M, Amoura Z et al. European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 2012;71:1771-82.
2. Henderson LK, Masson P, Craig JC et al. Induction and maintenance treatment of proliferative lupus nephritis: a meta-analysis of randomized controlled trials. Am J Kidney Dis 2013;61:74-87.
3. Liu LL, Jiang Y, Wang LN et al. Efficacy and safety of mycophenolate mofetil versus cyclophosphamide for induction therapy of lupus nephritis: a meta-analysis of randomized controlled trials. Drugs 2012;72:1521-33.
4. Lee YH, Woo JH, Choi SJ et al. Induction and maintenance therapy for lupus nephritis: a systematic review and meta-analysis. Lupus 2010;19:703-10.
5. Chan TM. Mycophenolate mofetil in the treatment of lupus nephritis-7 years on. Lupus 2008;17:617-21.
6. Walsh M, Solomons N, Lisk L et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis with poor kidney function: a subgroup analysis of the Aspreva Lupus Management Study. Am J Kidney Dis 2013;61: 710-5.
7. Tang Z, Yang C, Yu C et al. Effects of mycophenolate mofetil in patients with crescentic lupus nephritis. Nephrology 2008;13:702-7.
8. Furie R, Looney RJ, Rovin B et al. Efficacy and safety of rituximab in subjects with active proliferative lupus nephritis (LN): results from the randomized, double-blind phase III LUNAR Study [abstract]. Arthritis Rheum 2009;60:S429.
9. Weidenbusch M, Römmele C, Schröttle A et al. Beyond the LUNAR trial. Efficacy of rituximab in refractory lupus nephritis. Nephrol Dial Transplant 2013;28:106-11.
10. Ramos-Casals M, Soto MJ, Cuadrado MJ et al. Rituximab in systemic lupus erythematosus: a systematic review of off-label use in 188 cases. Lupus 2009;18:767-76.
11. Diáz-Lagares C, Croca S, Sangle S et al. The UKBIOGEAS Registry. Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: Pooled data from European cohorts. Autoimmun Rev 2012;11:357-64.
12. Terrier B, Amoura Z, Ravaud P et al. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French autoimmunity and rituximab registry. Arthritis Rheum 2010;62:2458-66.
13. Ramos-Casals M, Diaz-Lagares C, Soto-Cardenas MJ et al. Rituximab therapy in lupus nephritis: current clinical evidence. Clin Rev Allergy Immunol 2011;40:159-69.
14. Sfikakis PP, Boletis JN, Lionaki S et al. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum 2005;52:501-13.
15. Camous L, Melander C, Vallet M et al. Complete remission of lupus nephritis with rituximab and steroids for induction and rituximab alone for maintenance therapy. Am J Kidney Dis 2008;52:346-52.
16. Moroni G, Gallelli B, Sinico RA et al. Rituximab versus oral cyclophosphamide for treatment of relapses of proliferative lupus nephritis: a clinical observational study. Ann Rheum Dis 2012;71:1751-2.
17. Gunnarsson I, Sundelin B, Jónsdóttir T et al. Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. Arthritis Rheum 2007;56:1263-72.
18. Leandro MJ, Cambridge G, Edwards JC et al. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology 2005;44:1542-5.
19. van Vollenhoven RF, Gunnarsson I, Welin-Henriksson E et al. Biopsy-verified response of severe lupus nephritis to treatment with rituximab (anti-CD20 monoclonal antibody) plus cyclophosphamide after biopsy-documented failure to respond to cyclophosphamide alone. Scand J Rheumatol 2004;33:423-7.
20. Roccatello D, Sciascia S, Rossi D et al. Intensive shortterm treatment with rituximab, cyclophosphamide and methylprednisolone pulses induces remission in severe cases of SLE with nephritis and avoids further immunosuppressive maintenance therapy. Nephrol Dial Transplant 2011;26:3987-92.
21. Vigna-Perez M, Hernández-Castro B, Paredes- Saharopulos O et al. Clinical and immunological effects of rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res Ther 2006;8:R83.
22. Boletis JN, Marinaki S, Skalioti C et al. Rituximab and mycophenolate mofetil for relapsing proliferative lupus nephritis: a long-term prospective study. Nephrol Dial Transplant 2009;24:2157-60.
23. Pepper R, Griffith M, Kirwan C et al. Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids. Nephrol Dial Transplant 2009;24: 3717-23.
24. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40:1725.
25. Weening JJ, D'Agati VD, Schwartz MM et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Am Soc Nephrol 2004;15:241-50.
26. Bombardier C, Gladman DD, Urowitz MB et al. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992;35:630-40.
27. Houssiau FA, Vasconcelos C, D'Cruz D et al. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis 2010;69:61-4.
28. Merrill JT, Neuwelt CM, Wallace DJ et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010;62:222-33.
29. Lu TY, Ng KP, Cambridge G et al. A retrospective sevenyear analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients. Arthritis Rheum 2009;61:482-7.
30. Li EK, Tam LS, Zhu TY et al. Is combination rituximab with cyclophosphamide better than rituximab alone in the treatment of lupus nephritis? Rheumatology 2009;48: 892-8.
31. Ezeonyeji AN, Isenberg DA. Early treatment with rituximab in newly diagnosed systemic lupus erythematosus patients: a steroid-sparing regimen. Rheumatology 2012; 51:476-81.
32. Condon MB, Ashby D, Pepper RJ et al. Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis 2013;72:1280-6.
33. Melander C, Sallée M, Trolliet P et al. Rituximab in severe lupus nephritis: early B-cell depletion affects long-term renal outcome. Clin J Am Soc Nephrol 2009;4:579-87.
34. Jónsdóttir T, Zickert A, Sundelin B et al. Long-term follow-up in lupus nephritis patients treated with rituximab-clinical and histopathological response. Rheumatology 2013;52:847-55.
35. Houssiau FA, D'Cruz D, Sangle S et al. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. Ann Rheum Dis 2010;69:2083-9.
36. Moroni G, Doria A, Mosca M et al. A randomized pilot trial comparing cyclosporine and azathioprine for maintenance therapy in diffuse lupus nephritis over four years. Clin J Am Soc Nephrol 2006;1:925-32.
37. Stone JH, Merkel PA, Spiera R et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010;363:221-32.